Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training: A randomized controlled trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training: A randomized controlled trial. / Jessen, Søren; Onslev, Johan; Lemminger, Anders Krogh; Backer, Vibeke; Bangsbo, Jens; Hostrup, Morten.
I: Scandinavian Journal of Medicine & Science in Sports, Bind 28, Nr. 10, 2018, s. 2114-2122.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training: A randomized controlled trial
AU - Jessen, Søren
AU - Onslev, Johan
AU - Lemminger, Anders Krogh
AU - Backer, Vibeke
AU - Bangsbo, Jens
AU - Hostrup, Morten
N1 - CURIS 2018 NEXS 193
PY - 2018
Y1 - 2018
N2 - Due to a high prevalence of asthma and exercise‐induced bronchoconstriction in elite athletes, there is a high use of beta2‐adrenoceptor agonists (beta2‐agonists) in the athletic population. While anabolic in rodents, no study has been able to detect hypertrophy in humans after chronic beta2‐agonist inhalation. We investigated whether inhaled beta2‐agonist, terbutaline, alters body composition and metabolic rate with and without concurrent exercise training in healthy young men. Sixty‐seven participants completed a 4‐week intervention of daily terbutaline (8 × 0.5 mg) or placebo treatment without concurrent training (habitual; n = 23), with resistance (n = 23) or endurance (n = 21) training 3 times weekly. Before and after the interventions, participant's body composition was determined by dual‐energy X‐ray absorptiometry and resting metabolic rate and substrate oxidation by indirect calorimetry. Terbutaline increased lean body mass by 1.03 kg (95% CI 0.29‐1.76; P < .05) and 1.04 kg (95% CI 0.16‐1.93; P < .05) compared to placebo in the habitual and resistance training group, respectively, but had no effect compared to placebo in the endurance training group [−0.56 kg (95% CI −1.74‐0.62; P > .05)]. Fat mass, bone mineral content, and resting metabolic rate did not change differently between treatments with the intervention. Daily inhalation of terbutaline in near‐therapeutic doses induces skeletal muscle growth. This observation should be a concern for antidoping authorities.
AB - Due to a high prevalence of asthma and exercise‐induced bronchoconstriction in elite athletes, there is a high use of beta2‐adrenoceptor agonists (beta2‐agonists) in the athletic population. While anabolic in rodents, no study has been able to detect hypertrophy in humans after chronic beta2‐agonist inhalation. We investigated whether inhaled beta2‐agonist, terbutaline, alters body composition and metabolic rate with and without concurrent exercise training in healthy young men. Sixty‐seven participants completed a 4‐week intervention of daily terbutaline (8 × 0.5 mg) or placebo treatment without concurrent training (habitual; n = 23), with resistance (n = 23) or endurance (n = 21) training 3 times weekly. Before and after the interventions, participant's body composition was determined by dual‐energy X‐ray absorptiometry and resting metabolic rate and substrate oxidation by indirect calorimetry. Terbutaline increased lean body mass by 1.03 kg (95% CI 0.29‐1.76; P < .05) and 1.04 kg (95% CI 0.16‐1.93; P < .05) compared to placebo in the habitual and resistance training group, respectively, but had no effect compared to placebo in the endurance training group [−0.56 kg (95% CI −1.74‐0.62; P > .05)]. Fat mass, bone mineral content, and resting metabolic rate did not change differently between treatments with the intervention. Daily inhalation of terbutaline in near‐therapeutic doses induces skeletal muscle growth. This observation should be a concern for antidoping authorities.
KW - Faculty of Science
KW - Physical activity
KW - Beta-agonist
KW - Adrenergic
KW - Athletes
KW - Doping
U2 - 10.1111/sms.13221
DO - 10.1111/sms.13221
M3 - Journal article
C2 - 29777633
VL - 28
SP - 2114
EP - 2122
JO - Scandinavian Journal of Medicine & Science in Sports
JF - Scandinavian Journal of Medicine & Science in Sports
SN - 0905-7188
IS - 10
ER -
ID: 196713436